Suppr超能文献

儿童 Takayasu 动脉炎的临床病程和预后因素:101 例患者超过 15 年的综合分析。

Clinical course and prognostic factors of childhood Takayasu's arteritis: over 15-year comprehensive analysis of 101 patients.

机构信息

State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

出版信息

Arthritis Res Ther. 2019 Jan 22;21(1):31. doi: 10.1186/s13075-018-1790-x.

Abstract

BACKGROUND

Childhood Takayasu's arteritis (c-TA) is scarcely reported but is characterized by devastating morbidity and mortality. This study aims to investigate the clinical course of c-TA and prognostic factors associated with rehospitalization and events including vascular complications, flares, and death.

METHODS

An ambispective study of 101 c-TA patients satisfying the American College of Rheumatology (ACR) criteria and/or the European League against Rheumatism (EULAR)/Pediatric Rheumatology International Trials Organization (PRINTO)/Pediatric Rheumatology European Society (PReS) criteria was conducted from January 2002 to December 2017. Data on demographic, clinical, laboratory, imaging, and therapeutic features were collected. Event-free survival, complication-free survival, flare-free survival, rehospitalization-free survival, and associated prognostic factors were assessed by Kaplan-Meier survival curve and propensity score analysis.

RESULTS

The median age at c-TA onset was 14 (interquartile range (IQR) 12-16) years and 76.2% were female. Hypertension (70.3%), blood pressure discrepancy (55.4%), bruits (51.5%), and pulse deficits (37.6%) were core presentations. Major vascular involvement included the renal artery (62.4%), abdominal aorta (42.6%), subclavian artery (43.6%), and carotid artery (42.6%). Glucocorticoids (78.2%), antihypertensive drugs (72.3%), antiplatelet agents (72.3%), and revascularization (57.4%) were made up the majority administered. At a median 2.4 (IQR 0.7-6.1) years of follow-up, events, rehospitalization, vascular complications, flares and death were observed in 44.6%, 37.6%, 44.6%, 26.7%, and 3%, respectively. The 5-year event-free survival, rehospitalization-free survival, vascular complication-free survival, and flare-free survival were 42.8%, 55.8%, 45.9%, and 62.3%, respectively. Body mass index (BMI) (hazard ratio (HR) = 0.49, 95% confidence interval (CI) 0.30-0.81, p = 0.005), stroke (HR = 7.37, 95% CI 2.35-23.1, p = 0.001), and revascularization (HR = 0.51, 95% CI 0.27-0.94, p = 0.032) were independent prognostic predictors of events. Predictors for rehospitalization include age at admission (HR = 0.81, 95% CI 0.69-0.94, p = 0.006), renal artery involvement (HR = 0.49, 95% CI 0.25-0.96, p = 0.037), and elevated C-reactive protein (CRP; HR = 2.50, 95% CI 1.24-5.00, p = 0.01). BMI level (p = 0.024) and renal artery involvement (p = 0.015) were also associated with vascular complications, while revascularization (p = 0.002) independently correlated with re-flares.

CONCLUSIONS

This large ambispective study of c-TA revealed an early 3% mortality at the first year and around 50% morbidity within 5 years after diagnosis. Hypertension, renal artery involvement, and revascularization based on anti-inflammation, antihypertension, and antiplatelet medications dominated c-TA with indications for optimistic prognosis. Patients with initial lower BMI level, a younger age at admission, stroke, and elevated CRP have a high risk of poor outcomes, requiring close c-TA monitoring and more aggressive management.

TRIAL REGISTRATION

NCT03199183 , unique protocol ID: 2016-ZX43. June 26, 2017.

摘要

背景

儿童 Takayasu 动脉炎(c-TA)罕见报道,但具有严重的发病率和死亡率。本研究旨在调查 c-TA 的临床病程和与再住院及血管并发症、发作和死亡相关的预后因素。

方法

2002 年 1 月至 2017 年 12 月,对满足美国风湿病学会(ACR)标准和/或欧洲抗风湿病联盟(EULAR)/儿科风湿病国际临床试验组织(PRINTO)/儿科风湿病欧洲学会(PReS)标准的 101 例 c-TA 患者进行了前瞻性研究。收集了人口统计学、临床、实验室、影像学和治疗特征的数据。通过 Kaplan-Meier 生存曲线和倾向评分分析评估无事件生存、无并发症生存、无发作生存和再住院生存情况及其相关的预后因素。

结果

c-TA 发病的中位年龄为 14 岁(四分位距(IQR) 12-16 岁),76.2%为女性。高血压(70.3%)、血压差异(55.4%)、杂音(51.5%)和脉搏缺失(37.6%)是核心表现。主要血管受累包括肾动脉(62.4%)、腹主动脉(42.6%)、锁骨下动脉(43.6%)和颈动脉(42.6%)。糖皮质激素(78.2%)、抗高血压药物(72.3%)、抗血小板药物(72.3%)和血管重建术(57.4%)是主要的治疗方法。中位随访 2.4 年(IQR 0.7-6.1 年)时,44.6%、37.6%、44.6%、26.7%和 3%的患者分别出现了事件、再住院、血管并发症、发作和死亡。5 年无事件生存率、再住院生存率、无血管并发症生存率和无发作生存率分别为 42.8%、55.8%、45.9%和 62.3%。体重指数(BMI)(风险比(HR)=0.49,95%置信区间(CI)0.30-0.81,p=0.005)、中风(HR=7.37,95%CI 2.35-23.1,p=0.001)和血管重建术(HR=0.51,95%CI 0.27-0.94,p=0.032)是事件的独立预后预测因素。再住院的预测因素包括入院时的年龄(HR=0.81,95%CI 0.69-0.94,p=0.006)、肾动脉受累(HR=0.49,95%CI 0.25-0.96,p=0.037)和 C 反应蛋白(CRP)升高(HR=2.50,95%CI 1.24-5.00,p=0.01)。BMI 水平(p=0.024)和肾动脉受累(p=0.015)与血管并发症有关,而血管重建术(p=0.002)与再发作独立相关。

结论

本项 c-TA 的大样本前瞻性研究显示,发病后第 1 年的死亡率约为 3%,5 年内的发病率约为 50%。高血压、肾动脉受累和基于抗炎、降压和抗血小板治疗的血管重建术是 c-TA 的主要表现,预示着预后良好。初诊时 BMI 水平较低、入院时年龄较小、中风和 CRP 升高的患者发生不良结局的风险较高,需要密切监测 c-TA 并采取更积极的治疗措施。

试验注册

NCT03199183,唯一方案 ID:2016-ZX43。2017 年 6 月 26 日。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dea5/6341556/c5a222d90daf/13075_2018_1790_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验